8,344 reports of this reaction
2.0% of all QUETIAPINE reports
#6 most reported adverse reaction
DIABETES MELLITUS is the #6 most commonly reported adverse reaction for QUETIAPINE, manufactured by H2-Pharma, LLC. There are 8,344 FDA adverse event reports linking QUETIAPINE to DIABETES MELLITUS. This represents approximately 2.0% of all 427,224 adverse event reports for this drug.
QUETIAPINE has an overall safety score of 85 out of 100. Patients taking QUETIAPINE who experience diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETES MELLITUS is a less commonly reported adverse event for QUETIAPINE, but still significant enough to appear in the safety profile.
In addition to diabetes mellitus, the following adverse reactions have been reported for QUETIAPINE:
The following drugs have also been linked to diabetes mellitus in FDA adverse event reports:
DIABETES MELLITUS has been reported as an adverse event in 8,344 FDA reports for QUETIAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETES MELLITUS accounts for approximately 2.0% of all adverse event reports for QUETIAPINE, making it a notable side effect.
If you experience diabetes mellitus while taking QUETIAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.